IDEXX LABORATORIES INC /DE — Form 8-K
Filed November 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
IDEXX reported Q3 2026 revenue of $1,214M (+10% organic), with CAG Diagnostics recurring revenue up 11%. The company placed 1,900+ inVue Dx analyzers (installed base ~11,000), acquired AI diagnostic tool CoVet, and raised full-year 2026 revenue guidance to $4,741–$4,767M (from $4,700–$4,745M), organic growth to 9.3–10.0% (from 8.5–9.7%), and EPS to $14.96–$15.16 (from $14.69–$14.94), a $0.25 midpoint increase.
Why this rating
Strong organic revenue growth and instrument placements are real operational wins; guidance raise of $32M midpoint (~0.7% of $4.75B guidance) is meaningful but modest relative to $42.9B market cap. CoVet acquisition immaterial ($5M 2026 impact). Results confirm momentum but no transformational shift.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.